North American Policies are Accelerating Cannabis Market Growth

NEW YORK, June 8, 2018 /PRNewswire/ -- According to a report by Ameri Research Inc., the global legal cannabis market was valued at USD 14.3 Billion in 2016 and is projected to grow to USD 63.5 Billion by 2024 while maintaining a CAGR of 21.1% during the forecast period. The cannabis market is experiencing a period of healthy growth due to increasing legalization and decriminalization of cannabis products across North America. The report also explains that legalization movements are affecting policies beyond the U.S. region. Data by Arcview Market Research clarifies that growth of the legal cannabis industry is expected to re-accelerate in 2018, as adult-use sales ramp up in Canada, California, and Massachusetts along with first time medical sales in Florida. Body and Mind Inc. (OTC: BMMJ), mCig, Inc. (OTC: MCIG), GB Sciences, Inc. (OTC: GBLX), Abattis Bioceuticals Corp. (OTC: ATTBF), MPX Bioceutical Corp. (OTC: MPXEF)

In a report by Benzinga, Viridian Capital President Scott Greiper points out that the cannabis market received USD 1.23 Billion in investments during the first five weeks of 2018, up from USD 178 Million a year earlier. Viridian Capital Advisors' Vice President Harrison Phillips explained: "Investments in cultivation and retail this year have been driven predominantly by the Canadian player. This has been happening pretty consistently from late 2016 through 2017. This reflects the necessity to scale cannabis businesses, to get some kind of advantage, and to explore strategic opportunities, both through acquisitions and international expansion."

Body and Mind Inc. (OTC: BMMJ) also listed on the Canadian Securities Exchange under the Ticker (CSE: BAMM). Yesterday the company announced breaking news that the "Company and its strategic in-state investment partners received notification that the State of Ohio awarded a medical cannabis dispensary license to NMG, Ohio LLC ("NMG Ohio", "Applicant"). The Company's subsidiary, Nevada Medical Group LLC ("NMG") currently has a 30% ownership interest in NMG Ohio and is currently pursuing an option to increase its ownership position. It is anticipated that NMG will sign a management agreement in the near term to become operator of the dispensary.

Ohio Medical License Highlights:

        1) Obtained 1 of only 56 medical cannabis dispensary licenses awarded by State of
          Ohio, a state which has a population of approx. 11.5 Million.
        2) Location of license is in the city of Elyria, Lorain County, Northeastern Ohio.
        3) Only 3 medical dispensaries awarded in Lorain County, a county which has a population
          of approximately 300,000+.
        4) State of Ohio received approximately 370+ medical cannabis dispensary license
        5) First-mover position in Ohio provides the Company with the ability to expediently
          expand its Body and Mind brand name to another state.


Robert Hasman, President of NMG, stated "We are very pleased with our group being awarded one of the dispensary licenses located in Ohio and confirms the commitment and skill of our team. We have worked hard to submit numerous low cost strategic license applications to grow the company and create shareholder value. We currently have the following additional license applications pending and/or in progress as follows:"

        1) Ohio - NMG Ohio has 1 production license application submitted and in progress.
          NMG Ohio's cultivation license is currently going through an appeal process.
        2) Arkansas - 2 dispensary applications submitted and in progress. One cultivation
          license initially denied, however an Arkansas judge barred the issuance of any
          cultivation licenses and the process is currently, or expected to be shortly, under
          review by the Arkansas Supreme Court. The Arkansas submissions are under Letter of
          Intent between NMG and an in-state investor group (the "Investor Group"), who have
          agreed to fund the application process.


In the event the application is successful, Body and Mind will manage the Arkansas operations with terms to be determined. Both parties have agreed to finance the construction and start-up costs on a 75% BAM and 25% Investor Group basis, with BAM's contribution convertible up to a 40% equity interest in the Investor Group.

        1) Nevada - NMG has 2 dispensary applications nearing submission. It is anticipated
          that the Nevada Department of Taxation will be seeking applications from existing
          Medical Marijuana Certificate owner(s) to be awarded Medical Marijuana Dispensary
          Registration Certificates in the next 60 to 90 days. This application process is only
          open to existing Nevada license holders with Nevada having a limited number of
          dispensary, cultivation and production licenses. The Company has secured highly
          desirable real estate for both applications. The company has submitted a special use
          permit on one location and is finalizing submissions for the second location.  Both
          locations are in high traffic, underserved areas of Las Vegas.


Pepper Lane North Update: In 2017, a real estate investment group, led by the NMG's president, initiated the purchase of an approximately 30,000 square foot building adjacent to the existing NMG facility. In May 2018, the real estate investment group completed the purchase of the Pepper Lane North building and now owns the facility. The Company recently made the decision to terminate its lease back agreement regarding the Pepper Lane North facility as it was unable to relocate a church that was leasing office space in a building which is in close proximity to the Pepper Lane North facility. The Pepper Lane North building may still be an opportunity for the Company to lease storage and administrative space and the Company will continue to evaluate this opportunity."

mCig, Inc. (OTC: MCIG) is a diversified company servicing the legal cannabis, hemp and CBD markets via its lifestyle brands. mCig, Inc. is committed to be the leading distributor of technology, products, and services to fit the needs of a rapidly expanding industry. mCig, Inc., a diversified company servicing the legal cannabis markets is pleased to have announced on May 31st, 2018 they have closed escrow on the purchase of a 2.5 acre parcel in California City, CA. MCIG's agriculture division, with its Hemp farms in New York will soon expand from sea-to-sea with cultivating, extracting, and distribution operations in both New York and California. MCIG has begun the planning of an indoor cultivation facility to produce high quality, "California-Style" cannabis products after receiving three of the seven recreational cannabis licenses granted by California City allowing cultivation, manufacturing, and distribution. MCIG CEO Paul Rosenberg stated: "We are very grateful to the City of California City for their professionalism and thorough vetting process during licensing. We want to be a flagship facility and model licensee among the other licensed producers in the city. It is our sincere objective to create jobs, give back to the community, and create healthy products that compliment our current product lines and brands."

GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. GB Sciences, as previously reported, plans to file an Exploratory IND and perform a Phase 0 Clinical Trial to gather valuable First-In-Human data, to support clinical development decisions on prioritizing among multiple, related Parkinson's Disease ("PD") formulations. GB Sciences has a patent application covering multiple, related PD-formulas that are based on complex mixtures of minor cannabinoids and terpenes from cannabis chemovars. "The challenge we have encountered in approaching the US FDA is that we may not be able to use cannabis-based materials that GB Sciences has developed in the US for our clinical trials, " explains Dr. Andrea Small-Howard, Chief Science Officer of GB Sciences. "We are committed to complying with all federal requirements, even though we believe we can implement a system for growing and extracting here that exceeds the quality and consistency of the materials that we could obtain from the only federally-approved cannabis source for research in the US."

Abattis Bioceuticals Corp. (OTCQB: ATTBF) is a life sciences and biotechnology company which aggregates, integrates, and invests in cannabis technologies and biotechnology services for the legal cannabis industry developing in Canada. The company recently signed a letter of intent to integrate BLOCKStrain's proprietary technology into Abattis's product and services ecosystem. Through their collaboration, the parties hope to enable Abattis clients to instantly arrange for sales, shipping, testing and analysis of Abattis products and give clients comprehensive visibility over such products over their entire lifecycles. BLOCKStrain's platform, which stores all testing data in a blockchain-protected database, significantly reduces the workload and costs associated with product and genetic testing. "Our agreement with BLOCKStrain will help streamline and improve our offerings even further, and we are very excited to work on the development of our joint technologies," said Abattis President and CEO Rob Abenante.

MPX Bioceutical Corp. (OTCQB: MPXEF) an Ontario corporation, through its wholly owned subsidiaries in the U.S., provides substantial management, staffing, procurement, advisory, financial, real estate rental, logistics and administrative services to three medicinal cannabis enterprises in Arizona operating under the Health for Life and the award-winning Melting Point Extracts brands. The company recently announces the official opening of its newest "Health for Life" medical marijuana dispensary in the Metropolitan Phoenix area. This brings the number of dispensaries under MPX management in Arizona's Sun Valley to four. The Crismon dispensary will meet the needs of patients in this comparatively underserviced southeast quadrant of the region by making available the full spectrum of MPX concentrates, an extensive variety of cannabis flower, and a broad selection of 3rdparty, processed cannabis-infused edibles. The company also announced that it has relocated the processing and production of MPX concentrates to a new location in North Mesa. The new facility incorporates some of the most modern and innovative extraction and distillation technologies available, permitting MPX's expert processing team to produce a wide variety of products including oil cartridges, cured resin, shatter, resin sauce etc., all marketed under the MPX ("Melting Point Extracts") brand and advertised as the "Gold Standard" of cannabis concentrates.

Subscribe Now! Watch us report LIVE Follow us on Twitter for real time Financial News Updates: Follow and talk to us on Instagram: Facebook Like Us to receive live feeds:

About, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For body and mind inc, financial news dissemination and PR services, has been compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: .


        Media Contact:   






Back to news